Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dong-Jing Fu

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
BMC Psychiatry|February 25, 2014
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitateJennifer Kern Sliwa, Dong-Jing Fu, Cynthia A Bossie, et al.
Neuropsychiatric Disease and Treatment|September 8, 2012
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al.
Journal of Patient-Reported Outcomes|July 11, 2022
Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal sprayHeather Rozjabek, Nan Li, Holger Hartmann, et al.
Journal of Affective Disorders|March 23, 2013
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depressionIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
International Clinical Psychopharmacology|July 20, 2016
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophreniaBennett Levitan, Michael Markowitz, Ibrahim Turkoz, et al.
CNS Spectrums|July 29, 2022
Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIREIbrahim Turkoz, Oliver Lopena, Giacomo Salvadore, et al.
Clinical and Translational Science|April 2, 2026
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational ScienceMatthijs W van Hoogdalem, Dong-Jing Fu, Wayne C Drevets, et al.
Annals of General Psychiatry|July 13, 2013
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesMichael Markowitz, Dong-Jing Fu, Bennett Levitan, et al.
Therapeutic Advances in Psychopharmacology|August 29, 2013
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialCynthia A Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, et al.
Innovations in Clinical Neuroscience|July 9, 2015
Comparing Injection Site Pain with Paliperidone Palmitate Versus First-Generation Depot Antipsychotics in Subjects with SchizophreniaSrihari Gopal, Teresa Palermo, Jennifer Kern Sliwa, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
BMC Psychiatry|February 25, 2014
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitateJennifer Kern Sliwa, Dong-Jing Fu, Cynthia A Bossie, et al.
Neuropsychiatric Disease and Treatment|September 8, 2012
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaJennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al.
Journal of Patient-Reported Outcomes|July 11, 2022
Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal sprayHeather Rozjabek, Nan Li, Holger Hartmann, et al.
Journal of Affective Disorders|March 23, 2013
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depressionIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.
International Clinical Psychopharmacology|July 20, 2016
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophreniaBennett Levitan, Michael Markowitz, Ibrahim Turkoz, et al.
CNS Spectrums|July 29, 2022
Treatment response to esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior without evidence of early response: a pooled post hoc analysis of ASPIREIbrahim Turkoz, Oliver Lopena, Giacomo Salvadore, et al.
Clinical and Translational Science|April 2, 2026
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational ScienceMatthijs W van Hoogdalem, Dong-Jing Fu, Wayne C Drevets, et al.
Annals of General Psychiatry|July 13, 2013
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesMichael Markowitz, Dong-Jing Fu, Bennett Levitan, et al.
Therapeutic Advances in Psychopharmacology|August 29, 2013
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialCynthia A Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, et al.
Innovations in Clinical Neuroscience|July 9, 2015
Comparing Injection Site Pain with Paliperidone Palmitate Versus First-Generation Depot Antipsychotics in Subjects with SchizophreniaSrihari Gopal, Teresa Palermo, Jennifer Kern Sliwa, et al.
Pageof 8